Recombinetics is a recognized leader in gene editing to advance human and farm animal health and welfare.

Founded in 2008, Recombinetics is a privately held biotechnology company that aims at helping to solve some of the world’s most intractable challenges through gene editing. Recombinetics is delivering viable products and generating revenues today from the large and growing biomedical and agricultural markets.

Recombinetics focused its early stage development on the application of precision genetic technologies and active patent filings in animals. Development of advanced “gene-editing” technologies for commercial purposes began in 2011. Today, Recombinetics is widely recognized as the leader in livestock gene-editing and associated applied technologies for biomedical research, regenerative medicine, and animal agriculture.

Recombinetics’ first gene-edited animals are generating revenues today with a pipeline of animals under development for the large biomedical and agricultural markets.

Recombinetics is a company built on firsts.

With a robust intellectual property portfolio, RCI leverages its research platform to commercialize and deploy its invented and licensed technologies across key markets.
RCI’s growing global patent portfolio includes 25 issued patents, more than 300 additional applications filed, and first use and enabling patents for livestock for both CRISPR and TALENs. Here are some of RCI’s achievements in science.

2018

  • First gene edited thermotolerant cattle born

2017

  • First gene edited chickens produced in Europe
  • First genetically dehorned heifer born
  • First patent issued in China for gene editing large animals
  • First patent issued in Europe for gene editing large animals

2016-2008

  • First pig model of congenital heart failure developed
  • First pig model of polycystic kidney diseases developed
  • First-of-its-kind pig model of Neurofibromatosis Type 1 developed
  • First utility patent filed in the US for methods for producing transgenic pigs
  • First to make APOBEC pigs for PERV-safe organs
  • First DNA transposon engineered pig born
  • First genetically dehorned cattle born
  • First to gene-edit for accelerated reproduction OPU in cattle
  • First patent issued in the US for CRISPR gene editing in animals optimized to prevent re-cutting of the target sequence
  • First to achieve multi-gene editing in pigs and cattle
  • First to enable CRISPR in large animals
  • First filed CRISPR utility patents in large animals
  • First to transfer native allele in species
  • First TALENS use to knockout & break genes in embryos
Firsts in Biomedicine
Firsts in Agriculture
Firsts in Recombinetics Core Gene Editing Platform

 

Recombinetics collaborates with public and private leaders to deliver gene editing solutions.

Some key business highlights include: 

2018

  • Collaboration with Mayo Clinic announced to develop cardiomyocytes
  • Alliance to end castration of swine announced with collaborators in the United States and the Netherlands
  • Alliance to end dehorning of cattle announced with collaborators in Canada; first commercial deal for polled genetics
  • Brazil authorities concluded gene-edited dehorned cattle aren’t GMOs
  • Target TB announced with collaborators in Ireland and Northern Ireland to curb tuberculosis in cattle
  • 2017
  • Collaboration with Mayo Clinic announced to pig model of congenital heart failure
  • Collaboration with Children’s Minnesota announced to develop pig model of phenylketonuria
  • Announcement of major developments in neurofibromatosis Type 1 model funded by Children’s Tumor Foundation
Business Highlights in Biomedicine
Business Highlights in Agriculture

 

Our Science is Peer-Reviewed To Give the Public Assurances That Our Discoveries Are Checked for Accuracy. 

Our scientific findings are often published in peer-reviewed scientific journals and often cited by other scientists in their published research. Our work has been documented in over 300 peer-reviewed publications and written been covered many times by both scientific and consumer media outlets. Here are some of our recent publications:

About cancer
Engineered swine models of cancer Published in the Frontiers in Genetics

Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1 Published in Nature’s Communication Biology
A new tool for mapping breast cancer risk in the tumor microenvironment Published in Cancer Research

About cardiovascular disease
Peripheral vascular atherosclerosis in a novel PCSK9 gain-of-function mutant Ossabaw miniature pig model Published in Translational Research

About orphan disease
TALEN-based gene correction for epidermolysis bullosa Published in Molecular Therapy

About gene editing and advanced reproduction of pigs
In vivo genome editing using a high-efficiency TALEN system  Published in Nature
Precision editing of large animal genomes  Published in Advances in Genetics
Efficient TALEN-mediated gene knockout in livestock  Published in Proceedings of the National Academy of Sciences
Precise genome editing of PDX1 by direct injection of transcription activator-like effector nucleases (TALENS) into Parthenogenetic Pig Embryos Published in Reproduction, Fertility and Development
Efficient Nonmeiotic Allele Introgression in Livestock Using Custom EndonucleasesPublished in Proceedings of National of the National Academy of Sciences
Editing Livestock Genomes with Site-Specific Nucleases Published in the Journal of Reproduction, Fertility and Development
Live pigs produced from genome edited zygotes Published in Scientific Reports
TALEN-mediated gene targeting in porcine spermatogonia Published in Molecular Reproduction and Development
Simple and efficient methods for enrichment and isolation of endonuclease modified cells Published in PLOS One

See What the Media Stays

Our science is often covered by the media helping to educate the public on gene editing. Here are some of our media highlights:

Check out other media stories in our online Newsroom.